By loading the video, you agree to YouTube’s privacy policy.
Learn more
Speaker | Stefan Ledinger, MA BSc
Affiliation | biocrates life sciences, Innsbruck, Austria
Metabolomics as a tool to stratify patients and guide therapeutic decisions
In spite of major advances in the treatment of numerous diseases, non-response and loss of response to therapy is still an important topic. In addition, actionable biomarkers are largely missing for indications beyond oncology, as well as for the choice of supportive therapy. Here, metabolomics can be used to develop tools to help guide therapy decisions in multiple ways, e.g. predict whether a drug will be effective, choose the best course of therapy, or monitor therapies along the patient journey.
Related videos
Host-microbial interactions as pathophysiological nexus in inflammatory bowel disease
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Related articles
- Metabolite of the month – Trimethylamine N-oxide (TMAO)
- 3-indoleacetic acid (3-IAA) – Metabolite of the month
- p-cresol sulfate – Metabolite of the month
- The study of pre-diagnostic serum samples from the Norwegian Trøndelag Health Study (HUNT2 study) shows age-dependent differences linked to breast cancer risk
- Metabolomics and application in colorectal cancer research
